Actionable news
All posts from Actionable news
Actionable news in ADAP: Adaptimmune Therapeutics PLC,

Adaptimmune Announces SPEAR T-cells(TM) Brand for Proprietary Technology

PHILADELPHIA and OXFORD, United Kingdom, Apr 22, 2016 (GLOBE NEWSWIRE via COMTEX) --

Adaptimmune Therapeutics plc ADAP, +5.83% a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells(TM) (Specific Peptide Enhanced Affinity Receptor T-cells) to describe its proprietary technology.

The SPEAR T-cells brand is intended to symbolize the vital role that Adaptimmune's enhanced affinity T-cell receptors play in targeting cancer.

Adaptimmune has a history of scientific leadership in the field of T-cell engineering and the company's proprietary T-cell engineering platform, developed over the last 15 years, has generated a strong pipeline of T-cell therapies.

"Affinity optimized T-cell receptors are essential to the fight against cancer," said James Noble, Adaptimmune's Chief Executive Officer. "Our SPEAR T-cell technology is unique in delivering correctly identified targets and enhanced affinity TCRs that have the potency needed to attack tumors, but also the optimum specificity to minimize risks of cross-reactivity. Our proprietary technology provides us with 'supra-natural' TCRs that enable the acceleration of our programs and also...